Sangamo Therapeutics, Inc.SGMONASDAQ
LOADING
|||
Switch Symbol:
Net Income Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year net income growth rate
Latest
-74.77%
↑ 30% above average
Average (39q)
-107.07%
Historical baseline
Range
High:140.66%
Low:-2519.61%
CAGR
+1.0%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -74.77% |
| Q2 2025 | 34.68% |
| Q1 2025 | -30.78% |
| Q4 2024 | -319.23% |
| Q3 2024 | 129.54% |
| Q2 2024 | 26.40% |
| Q1 2024 | 18.59% |
| Q4 2023 | 42.11% |
| Q3 2023 | 9.03% |
| Q2 2023 | -641.84% |
| Q1 2023 | 140.66% |
| Q4 2022 | 2.22% |
| Q3 2022 | -23.12% |
| Q2 2022 | 1.83% |
| Q1 2022 | -17.28% |
| Q4 2021 | 21.37% |
| Q3 2021 | -1.10% |
| Q2 2021 | -2.69% |
| Q1 2021 | -13.12% |
| Q4 2020 | -2519.61% |
| Q3 2020 | 95.69% |
| Q2 2020 | 16.27% |
| Q1 2020 | -1042.11% |
| Q4 2019 | 116.68% |
| Q3 2019 | 9.83% |
| Q2 2019 | 28.15% |
| Q1 2019 | -125.84% |
| Q4 2018 | -45.32% |
| Q3 2018 | 22.82% |
| Q2 2018 | 17.57% |
| Q1 2018 | -54.21% |
| Q4 2017 | -5.97% |
| Q3 2017 | 1.10% |
| Q2 2017 | 24.90% |
| Q1 2017 | -72.82% |
| Q4 2016 | 49.25% |
| Q3 2016 | 28.64% |
| Q2 2016 | -61.12% |
| Q1 2016 | -17.70% |
| Q4 2015 | -51.57% |